{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:48:54Z","timestamp":1788407334571,"version":"build-2803163510"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Reprod. Health"],"abstract":"<jats:p>The widespread use of combination antiretroviral therapy has transformed HIV infection into a chronic condition, with life expectancy of people with HIV (PWH) approaching that of the general population when treatment is initiated early and virological suppression is maintained. As survival has improved, the demographic profile of the HIV population has shifted substantially, with a growing proportion of PWH in high-income countries now aged 50 years and older. In this context, the goals of HIV care extend beyond durable virological suppression to include long-term tolerability, management of multimorbidity, reduction of polypharmacy-related risks, and preservation of functional status and quality of life. Three-drug antiretroviral regimens (3DR) have long represented the standard of care due to their robust efficacy and high genetic barrier to resistance. However, in aging and comorbid PWH, lifelong exposure to multiple antiretroviral agents may increase the risk of cumulative organ toxicity\u2014including renal, bone, and cardiovascular adverse effects\u2014as well as clinically relevant drug\u2013drug interactions with medications used to manage concomitant conditions. These considerations have driven interest in treatment simplification strategies, with dual antiretroviral therapy (2DR) emerging as the most clinically investigated approach. Current international guidelines endorse specific 2DR strategies on the basis of randomized controlled trials demonstrating non-inferior virological efficacy compared with 3DR in carefully selected populations. This narrative review integrates evidence from randomized trials and real-world observational studies to critically appraise the role of guideline-endorsed 2DR vs. 3DR in aging and comorbid PWH. We highlight clinical scenarios in which simplification may be advantageous, identify factors associated with reduced durability, and propose a patient-centred framework to support individualized antiretroviral therapy selection, one that extends beyond virological endpoints to incorporate the geriatric dimensions of contemporary HIV care.<\/jats:p>","DOI":"10.3389\/frph.2026.1805648","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:35:42Z","timestamp":1782102942000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review"],"prefix":"10.3389","volume":"8","author":[{"given":"Maria Vittoria","family":"Cossu","sequence":"first","affiliation":[{"name":"ASST Fatebenefratelli Sacco","place":["Milan, Italy"]},{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Matone","sequence":"additional","affiliation":[{"name":"ASST Fatebenefratelli Sacco","place":["Milan, Italy"]},{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Iannone","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Fusetti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Colombo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]},{"name":"Department of Biomedical and Clinical Sciences \u201cL. Sacco\u201d, University of Milan","place":["Milan, Italy"]},{"name":"Centre for Multidisciplinary Research in Health Science (MACH)","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lisa","family":"Ridolfo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gervasoni","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, ASST Fatebenefratelli Sacco University Hospital","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1506816","article-title":"Initiation of antiretroviral therapy in early asymptomatic HIV infection","volume":"373","year":"2015","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e0207005","DOI":"10.1371\/journal.pone.0207005","article-title":"Global and regional trends of people living with HIV aged 50 and over: estimates and projections for 2000\u20132020","volume":"13","author":"Autenrieth","year":"2018","journal-title":"PLoS One"},{"key":"B3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s11904-019-00464-3","article-title":"Aging with HIV","volume":"16","author":"Guaraldi","year":"2019","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3390\/v18030387","article-title":"Medication burden and adherence of antiretroviral therapy among older people living with HIV in the context of multimorbidity and polypharmacy: a multicenter study","volume":"18","author":"Zhou","year":"2026","journal-title":"Viruses"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S0140-6736(13)61809-7","article-title":"The end of AIDS: HIV infection as a chronic disease","volume":"382","author":"Deeks","year":"2013","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1146\/annurev-med-042909-093756","article-title":"HIV Infection, inflammation, immunosenescence, and aging","volume":"62","author":"Deeks","year":"2011","journal-title":"Annu Rev Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11904-012-0118-8","article-title":"HIV And inflammation: mechanisms and consequences","volume":"9","author":"Hunt","year":"2012","journal-title":"Curr HIV\/AIDS Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1089\/apc.2015.0199","article-title":"The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients","volume":"30","author":"Krentz","year":"2016","journal-title":"AIDS Patient Care STDS"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B10","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/cid\/ciac130","article-title":"Efficacy and safety of switching to the 2-drug regimen dolutegravir\/lamivudine versus continuing a 3- or 4-drug regimen for maintaining virologic suppression in adults living with human immunodeficiency virus 1 (HIV-1): week 48 results from the phase 3, noninferiority SALSA randomized trial","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide-based 3- or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: phase 3, randomized, noninferiority TANGO study","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/jac\/dkx169","article-title":"Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study","volume":"72","author":"Nozza","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-Acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e679","DOI":"10.1016\/S2352-3018(21)00185-5","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study","volume":"8","author":"Jaeger","year":"2021","journal-title":"Lancet HIV"},{"key":"B18","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1111\/hiv.13146","article-title":"Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: data from real-life ODOACRE cohort","volume":"22","author":"Fabbiani","year":"2021","journal-title":"HIV Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1093\/cid\/cir627","article-title":"Premature age-related comorbidities among HIV-infected persons compared with the general population","volume":"53","author":"Guaraldi","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1004078","DOI":"10.1371\/journal.ppat.1004078","article-title":"HIV-infected individuals with low CD4\/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality","volume":"10","author":"Serrano-Villar","year":"2014","journal-title":"PLoS Pathog"},{"key":"B21","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0203821","DOI":"10.1128\/aac.02038-21","article-title":"Forgiveness of INSTI-containing regimens at drug concentrations simulating Variable adherence in vitro","volume":"66","author":"Acosta","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"B23","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"B24","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/hiv.70187","article-title":"Effectiveness and safety of two-drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: data from the COMBINE-2 study","volume":"27","author":"Mussini","year":"2026","journal-title":"HIV Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/cid\/ciae500","article-title":"Viral suppression rates at 48 weeks in people with HIV starting long-acting cabotegravir\/rilpivirine with initial viremia","volume":"80","author":"Hickey","year":"2025","journal-title":"Clin Infect Dis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1056\/NEJMoa2508228","article-title":"Cabotegravir plus Rilpivirine for persons with HIV and adherence challenges","volume":"394","author":"Rana","year":"2026","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12879-025-10499-0","article-title":"Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data","volume":"25","author":"Iannone","year":"2025","journal-title":"BMC Infect Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1097\/QAD.0000000000004437","article-title":"Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics","volume":"40","author":"Padilla","year":"2026","journal-title":"AIDS"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.3390\/v17081108","article-title":"Safety, tolerability, and metabolic effects of long-acting cabotegravir and rilpivirine in HIV care: a comprehensive review","volume":"17","author":"Bottanelli","year":"2025","journal-title":"Viruses"},{"key":"B30","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/hiv.70114","article-title":"Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: real-world data from the Spanish RELATIVITY cohort","volume":"27","author":"Troya","year":"2026","journal-title":"HIV Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"ofaf368","DOI":"10.1093\/ofid\/ofaf368","article-title":"Optimizing the use of cabotegravir plus rilpivirine long-acting therapy in HIV care: evidence, implementation, and unanswered questions","volume":"12","author":"Geretti","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Frontiers in Reproductive Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2026.1805648\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:35:53Z","timestamp":1782102953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/frph.2026.1805648\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":31,"alternative-id":["10.3389\/frph.2026.1805648"],"URL":"https:\/\/doi.org\/10.3389\/frph.2026.1805648","relation":{},"ISSN":["2673-3153"],"issn-type":[{"value":"2673-3153","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1805648"}}